News Archive

EUSA Pharma announces the successful conclusion of the EMR Procedure for Rapydan®.

18 October 2007.

EUSA Pharma today announced the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007. Rapydan®, a rapid-onset anesthetic patch, is EUSA’s lead product in the large and growing pain market.

Rapydan® achieved regulatory approval in Sweden in January 2007 and is also marketed in the USA by Endo under the brand name Synera™.

Rapydan® is a medicated plaster,
which combines two local anesthetic agents, lidocaine and tetracaine. Rapydan®’s key differentiator is the inclusion in the patch of a heating element that aids the speed of onset and
penetration of the anesthesia. It is indicated for surface anesthesia of the skin in connection with
needle puncture in adults and children from
3 years of age.

Download PDF
of transcript (76KB)